skip to the content

Clinical Trials

Allogeneic HSCT in Pediatric Solid Tumors and Lymphomas

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Relapsed and/or Chemotherapy Resistant Pediatric Solid Tumors and Lymphomas using Nonmyeloablative Reduced Intensity Conditioning

Protocol ID

05-016T

Protocol Description

Blood and bone marrow transplantation (BMT) is used as a treatment for many forms of cancer.  It involves giving high doses of treatment with chemotherapy to try and kill the cancer cells before bone marrow or stem cells are given to the patient.  Because of damage to the bone marrow, the marrow needs to be replaced by stem cells from a donor or from the patient. This is the standard care for transplantation in patients with cancer. A risk of this treatment is that it can cause injury to vital organs such as the lungs, liver and kidneys, from the chemotherapy and/or radiation. 

The purpose of this clinical research study is to evaluate the effectiveness of low intensity chemotherapy followed by an infusion of blood forming stem cells.

Eligibility Criteria

Patients with a diagnosis of a solid tumor or lymphoma that have developed progressive disease or are in partial remission in spite of standard doses of chemotherapy

Primary Investigator(s)

  • Indira Sahdev, MD

Contact Information

Nan Werther, RN, MS, CPON
(718) 470-3620
nwerther@lij.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Genetics:
top
top